Cipla Builds On Albuterol Share As Investors Await FY23 US Revenue Delta
No Definitive Decision Yet On Avenue Deal
Cipla signals more US momentum with headroom for albuterol market share expansion, promising prospects for generic Brovana and strong launch line-up in FY23, but analysts also keep close eye on regulatory pre-approval inspection timelines.
You may also be interested in...
Generic Revlimid and lanreotide propel Cipla’s US business to a high in the fiscal second quarter, with products like leuprolide depot set for debut ‘any time now’. Management signals cost edge for generic Advair as it awaits further word following a FDA establishment inspection report at its Indian site, while a Plan B is being initiated for generic Abraxane.
Cipla readies scale-up in peptide injectables with five filings in the US and gears for upcoming high-value launches for generic versions of Advair, Revlimid and Abraxane. The company is also exploring partnering opportunities for monkeypox.
Executive vice chairperson of Cipla Samina Hamied talks to Generics Bulletin about the company’s intention to become global lung leaders on the back of biosimilars opportunities and its inhalation assets. As well as discussing Cipla’s three-year strategy, Hamied – who is also the vice president of IPA – discusses creating a favorable regulatory and policy landscape in India.